Hackensack Researchers Present Transformative Studies at Annual Cancer Meeting
June 04, 2024
Presentations and publications focus on immunotherapy, cellular therapy, targeted therapy, and biomarker research for solid tumors and hematologic cancers
Researchers from Hackensack Meridian John Theurer Cancer Center (JTCC)—a research partner with Georgetown’s Lombardi Comprehensive Cancer Center, an NCI-designated comprehensive cancer center. —and Hackensack University Medical Center are reporting transformative results from 35 studies at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, the largest gathering of cancer professionals. The meeting was held May 31 through June 4 in Chicago.
Several of the studies focus on optimizing the use of immune-boosting and targeted therapies in combination with investigational or standard treatments for solid tumors such as those of the pancreas, kidney, lung, liver, breast, brain, colon/rectum, and ovaries. Others highlight advances in the use of stem cell transplantation and other approaches to treat blood cancer such as multiple myeloma, leukemia, and lymphoma. Investigators are also presenting data on RNA-based technologies to monitor treatment response in people with cancer.
Immunotherapy and other novel treatments for solid tumors
- Phase 1 study of anti–immunoglobulin-like transcript 3 (ILT3) monoclonal antibody MK-0482 + pembrolizumab + gemcitabine + nab-paclitaxel (Gem/Nab-P) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC).
- Phase 2 trial of BXCL701 and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (EXPEL-PANC): Preliminary findings.
- Cln-619 (anti-MICA/B antibody) alone and in combination with pembrolizumab (P) for advanced solid tumors: Updated results of a Phase 1 study.
- Efficacy and safety of erdafitinib in adults with breast cancer and prespecified fibroblast growth factor receptor alterations in the phase 2 open-label, single-arm RAGNAR trial.
- Efficacy and safety of erdafitinib in adults with NSCLC and prespecified fibroblast growth factor receptor alterations in the phase 2 open-label, single-arm RAGNAR trial.
- Efficacy of erdafitinib in adults with advanced solid tumors and non-prespecified fibroblast growth factor receptor mutations in the phase 2 RAGNAR trial: Exploratory cohort.
- Phase 1 study of CTX-471, a novel CD137 agonist antibody, in patients with progressive disease following PD-1/PD-L1 inhibitors in metastatic or locally advanced malignancies.
- Phase 1 study of anti–immunoglobulin-like transcript 3 (ILT3) monoclonal antibody (mAb) MK-0482 + pembrolizumab (pembro) in patients with recurrent inoperable glioblastoma (GBM).
- Phase 1b study of NC410 in combination with pembrolizumab in immune checkpoint inhibitor (ICI) naïve, and refractory microsatellite stable (MSS)/microsatellite instability-low (MSI-L) colorectal cancer (CRC) and ovarian cancer.
- Combination treatment effect of an immunotherapeutic agent with microtubule inhibitors.
- First-in-human phase I trial of the oral first-in-class ubiquitin specific peptidase 1 (USP1) inhibitor KSQ-4279 (KSQi), given as single agent (SA) and in combination with olaparib (OLA) or carboplatin (CARBO) in patients (pts) with advanced solid tumors, enriched for deleterious homologous recombination repair (HRR) mutations.
- Phase 1/2 trial of the HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab: Clinical update.
Hematologic cancer management
- Effect of maintenance therapy (MT) on real-world outcomes (RWO) of patients (pts) with newly diagnosed multiple myeloma (NDMM) post stem cell transplant (SCT).
- Real-world outcomes (RWO) with tandem transplantation in patients (pts) with newly diagnosed multiple myeloma (NDMM).
- Mortality trends (1999-2022) in patients with multiple myeloma with pneumonia, influenza, and COVID-19.
- Post-ASCT consolidation with EPD or ERD in patients with high-risk multiple myeloma.
- Seven-year overall survival analysis from ECHELON-1 study of A+AVD versus ABVD in patients with previously untreated stage III/IV classical Hodgkin lymphoma.
- Clinical and sociodemographic factors associated with digital health literacy in patients with non-Hodgkin lymphoma or colorectal carcinoma.
- Impact of pacritinib on symptoms in with thrombocytopenia and myelofibrosis who require red blood cell transfusion.
- Epcoritamab with rituximab + lenalidomide (R2) in previously untreated (1L) follicular lymphoma (FL) and epcoritamab maintenance in FL: EPCORE NHL-2 arms 6 and 7.
- Ponatinib (PON) in patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) and the T315I mutation (mut): 4-year results from OPTIC.
- EPCORE NHL-1 follicular lymphoma (FL) cycle (C) 1 optimization (OPT) cohort: Expanding the clinical utility of epcoritamab in relapsed or refractory (R/R) FL.
- Multicenter, randomized phase II study of epcoritamab for patients with large B-cell lymphomas achieving a partial response after CD19-directed CAR T-cell therapy (CAR-T).
- Safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of KT-253, a targeted protein degrader of MDM2, in patients with relapsed/refractory (R/R) solid tumors, lymphoma, high grade myeloid malignancies and acute lymphoblastic leukemia (ALL).
- In-depth analysis of responders in the phase 3 PhALLCON trial of ponatinib vs imatinib in newly diagnosed Ph+ ALL.
Cellular therapies
- ATHENA: A phase 1/2 study of AZD5851, a chimeric antigen receptor (CAR) T-cell therapy directed against GPC3 in adult patients with advanced/recurrent hepatocellular carcinoma (HCC).
- Phase 1 trial of TSC-100 and TSC-101, engineered T cell therapies that target minor histocompatibility antigens to eliminate residual disease after hematopoietic cell transplantation.
- Patients (pts) with R/R large B-cell lymphoma (LBCL) treated with lisocabtagene maraleucel (liso-cel) nonconforming product (NCP) under the Expanded Access Protocol (EAP).
RNA and biomarker studies
- Using cell-free RNA in monitoring immune system and the demonstration of significant systemic deficiency in lymphoid and myeloid biomarkers in patients with cancer.
- Defining low-HER2 cancers using RNA quantification by next generation sequencing.
- Multiple alternative splicing of HER2 transcripts and exon skipping with potential consequences on function and antibody-based therapy.
- Expression of alternatively spliced BCMA RNA with skipping of transmembrane domain.
- The molecular landscape of PIWIL1 expression in colorectal adenocarcinoma (CRC).
- Developing behavioral intervention to support molecular testing of patients with biliary tract cancer.
Pediatric cancers